Sutro Biopharma’s luveltamab was granted orphan status by the FDA as a tazevibulin pediatric acute myeloid leukemia treatment, according to a post to the agency’s website. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on STRO:
- Sutro Biopharma to Participate in Upcoming Investor Conferences
- Credit Suisse to hold a conference
- Sutro Biopharma price target lowered to $20 from $30 at H.C. Wainwright
- Sutro Biopharma reports Q3 EPS (37c), consensus (74c)
- Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones